Articles Accepted

Alzheimer’s disease (AD) is a progressive, neurodegenerative disease which is caused mainly due to accumulation of an aberrant protein known as beta-amyloid in the form of senile plaques. However, over the past few years, network biology studies have indicated that classical “one drug-one target” hypothesis may not work in disease such as AD where the biochemical disease mechanisms are intricately interconnected. Therefore, multifunctional molecules which can modulate several targets could be key towards finding the therapeutics for this debilitating disorder. Keeping this in mind, several pyrazoline containing molecules with promising Abeta aggregation inhibition potential were explored further against key targets involved in AD such as cholinesterases, oxidative stress and advanced glycation end products (AGE). Some potential multifunctional molecules were identified as a result of this work.